ArticleCancers2020
Expansion of Circulating Tumor Cells from Patients with Locally Advanced Pancreatic Cancer Enable Patient Derived Xenografts and Functional Studies for Personalized Medicine.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Capture and Culture of Circulating Tumor Cells Using a Biodegradable 3D Scaffold for Patient-Derived Xenograft Construction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Reconstructing the metastatic journey: functional circulating tumor cells and disseminated tumor cells based models for translational oncology.Journal of experimental & clinical cancer research : CR · 2026Review
- Advancements in Circulating Tumor Cell Expansion Ex Vivo: A Matured Technology?Methods in molecular biology (Clifton, N.J.) · 2026Article
- Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis.Cancer cell international · 2025Review
- Longitudinal Circulating Tumor Cell Collection, Culture, and Characterization in Pancreatic Adenocarcinomas.Cancers · 2025Article
- Advanced Detection of Pancreatic Cancer Circulating Tumor Cells Using Biomarkers and Magnetic Particle Spectroscopy.Nanotheranostics · 2025Article
- CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches.Cell reports. Medicine · 2024Article
- Article
- Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.Clinical and translational medicine · 2024Review
- Single-Cell Proliferation Microfluidic Device for High Throughput Investigation of Replicative Potential and Drug Resistance of Cancer Cells.Cellular and molecular bioengineering · 2023Article
- Patient-derived tumor models and their distinctive applications in personalized drug therapy.Mechanobiology in medicine · 2023Review
- Circulating tumor cell-derived preclinical models: current status and future perspectives.Cell death & disease · 2023Review
- Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFβ Signaling Pathways andCancers · 2023Article
- Label-Free Separation of Circulating Tumor Cells and Clusters by Alternating Frequency Acoustic Field in a Microfluidic Chip.International journal of molecular sciences · 2023Article
- Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging.Frontiers in oncology · 2023Article
- Technologies for Viable Circulating Tumor Cell Isolation.International journal of molecular sciences · 2022Review
- Phenotyping of rare circulating cells in the blood of non-metastatic breast cancer patients using microfluidic Labyrinth technology.Biomicrofluidics · 2022Article
- Integrated Workflow for the Label-Free Isolation and Genomic Analysis of Single Circulating Tumor Cells in Pancreatic Cancer.International journal of molecular sciences · 2022Article
- A combination of circulating tumor cells and CA199 improves the diagnosis of pancreatic cancer.Journal of clinical laboratory analysis · 2022Article
- Synergistic Analysis of Circulating Tumor Cells Reveals Prognostic Signatures in Pilot Study of Treatment-Naïve Metastatic Pancreatic Cancer Patients.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Improvement in pancreatic cancer treatment represents an urgent medical goal that has been hampered by the lack of predictive biomarkers. Circulating Tumor Cells (CTCs) may be able to overcome this issue by allowing the monitoring of therapeutic response and tumor aggressiveness through ex vivo expansion. The successful expansion of CTCs is challenging, due to their low numbers in blood and the high abundance of blood cells. Here, we explored the utility of pancreatic CTC cultures as a preclinical model for treatment response. CTCs were isolated from ten patients with locally advanced pancreatic cancer using the Labyrinth, a biomarker independent, size based, inertial microfluidic separation device. Three patient-derived CTC samples were successfully expanded in adherent and spheroid cultures. Molecular and functional characterization was performed on the expanded CTC lines. CTC lines exhibited KRAS mutations, consistent with pancreatic cancers. Additionally, we evaluated take rate and metastatic potential in vivo and examined the utility of CTC lines for cytotoxicity assays. Patient derived expanded CTCs successfully generated patient derived xenograft (PDX) models with a 100% take rate. Our results demonstrate that CTC cultures are possible and provide a valuable resource for translational pancreatic cancer research, while also providing meaningful insight into the development of distant metastasis, as well as treatment resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.